JAK2 inhibitors are implicated across a broad range of difficult-to-treat illnesses, including cancer and autoimmune diseases, in which patients have mutations and rearrangements of the JAK2 gene. SB1518 (ONX 0803) is a small molecule JAK2-selective kinase inhibitor, which has demonstrated activity against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in myeloproliferative disorders such as myelofibrosis (MF). It is estimated that approximately 50% of patients with MF possess the JAK2 mutation. SB1518 (ONX 0803) also provides new development pathways for other hematologic malignancies with mutations and rearrangements in the JAK2 gene. At the recent American Society of Hematology annual meeting, investigators reported encouraging data for SB1518 (ONX 0803) in early stage clinical trials in myeoloproliferative and other hematologic disorders, such as leukemia and lymphoma.
Onyx can elect to exercise its exclusive options for SB1518 (ONX 0803) and SB1578 (ONX 0805) separately and independently at certain predetermined stages of development for each compound in all indications in the United States, Canada and Europe. S*BIO would retain rights to develop and commercialize SB1518 and SB1578 in the rest of the world.
About S*BIO Pte Ltd
S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC
|SOURCE S*BIO Pte Ltd; Onyx Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved